- Diseases
- Acoustic Neuroma (14)
- Adrenal Gland Tumor (24)
- Anal Cancer (68)
- Anemia (2)
- Appendix Cancer (16)
- Bile Duct Cancer (26)
- Bladder Cancer (68)
- Brain Metastases (28)
- Brain Tumor (230)
- Breast Cancer (720)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (156)
- Colon Cancer (164)
- Colorectal Cancer (112)
- Endocrine Tumor (4)
- Esophageal Cancer (42)
- Eye Cancer (36)
- Fallopian Tube Cancer (8)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (8)
- Kidney Cancer (126)
- Leukemia (344)
- Liver Cancer (50)
- Lung Cancer (286)
- Lymphoma (284)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (98)
- Myelodysplastic Syndrome (60)
- Myeloproliferative Neoplasm (4)
- Neuroendocrine Tumors (16)
- Oral Cancer (100)
- Ovarian Cancer (172)
- Pancreatic Cancer (164)
- Parathyroid Disease (2)
- Penile Cancer (14)
- Pituitary Tumor (6)
- Prostate Cancer (144)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (236)
- Skin Cancer (296)
- Skull Base Tumors (56)
- Spinal Tumor (12)
- Stomach Cancer (60)
- Testicular Cancer (28)
- Throat Cancer (90)
- Thymoma (6)
- Thyroid Cancer (96)
- Tonsil Cancer (30)
- Uterine Cancer (80)
- Vaginal Cancer (16)
- Vulvar Cancer (20)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (20)
- Advance Care Planning (10)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (362)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (632)
- Complementary Integrative Medicine (24)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (230)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (124)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (118)
- Molecular Diagnostics (8)
- Pain Management (62)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (908)
- Research (396)
- Second Opinion (74)
- Sexuality (16)
- Side Effects (606)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (402)
- Survivorship (322)
- Symptoms (184)
- Treatment (1784)
Melanoma faculty contribute to Nature Medicine's 2012 top advances
2 minute read | Published December 17, 2012
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on December 17, 2012
By Leslie Loddeke, Publications Coordinator, Melanoma Medical Oncology Department
MD Anderson Melanoma Medical Oncology Chair Patrick Hwu, M.D., and Professor Wen-Jen Hwu, M.D., Ph.D., were coauthors of one of the papers named in Nature Medicine's "Notable advances 2012" list of the year's top basic biomedical discoveries.
The article notes "certain areas of biomedicine saw fast-paced discovery this year" in presenting its list of "the papers that helped these fields advance quickly" in 2012.
Under the heading "Immunotherapy: Co-receptor clampdown," the article cited two papers that made the inhibitory co-receptor PD-1 (programmed cell death protein 1, found on T cells) "one of the darlings of the cancer immunotherapy field this year."A team led by scientists from the Johns Hopkins School of Medicine reported the findings of a study of a PD-1-specific antibody in patients with different types of cancer in a New England Journal of Medicine article, as well as those from a companion study in a second article, "Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer."
MD Anderson's two co-authors on the second study reflect the department's participation in the clinical trial. Wen-Jen Hwu was principal investigator at the MD Anderson site. In that study, researchers reported that "of 207 patients with advanced cancer who received an anti-PDL1 antibody, 6-17% of evaluable patients experienced an objective response (either complete or partial)," Nature Medicine noted.Despite the fact that it remains unknown why only certain tumors and patients responded to the antibodies, "these trials further validate immune modulation of T cell activity as a therapeutic approach to cancer treatment," Nature Medicine concluded.